Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune plans a webcast fireside chat at the Wells Fargo healthcare conference, offering investors online access to management’s remarks.
Rhea-AI Summary
Altimmune (ALT) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 9:30 a.m. ET.
The late clinical-stage biopharmaceutical company is developing pemvidutide for serious liver diseases, and will provide webcast access to the session via the Events section of its website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Second-quarter earnings | Neutral | -2.3% | Quarterly results and business update coincided with a negative 24-hour price reaction. |
| Aug 05 | Earnings scheduling notice | Neutral | -1.3% | Announcement scheduled second-quarter results and a management business update for August 12. |
| Aug 03 | Phase 3 trial initiation | Positive | +5.6% | Company began enrolling patients in the global PERFORMA Phase 3 MASH trial. |
| Jul 28 | Phase 2 clinical data | Positive | +1.0% | RECLAIM met its primary endpoint and reported favorable secondary alcohol-use-disorder results. |
| May 28 | Phase 2b clinical data | Positive | +3.0% | IMPACT data showed metabolic improvements across weight, lipids, and other measures. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical announcements aligned with gains in three of five recent events, while the earnings and scheduling announcements diverged with negative reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.
A webcast of the fireside chat will be available via the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
ir@altimmune.com
Media Contact:
Real Chemistry
altimmune@realchemistry.com
